Report cover image

Ocular Drug Industry Research Report 2025

Publisher APO Research, Inc.
Published Jul 02, 2025
Length 126 Pages
SKU # APRC20092706

Description

Summary

According to APO Research, the global Ocular Drug market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Ocular Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Ocular Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Ocular Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Ocular Drug include OCULAR THERAPEUTIX, INC, Alimera Sciences, Allergan, Plc, Clearside Biomedical, Envisia Therapeutics, EyeGate Pharma, Graybug Vision Inc, Taiwan Liposome Company and Valeant Pharmaceuticals International, Inc, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Ocular Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ocular Drug.

The report will help the Ocular Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

The Ocular Drug market size, estimations, and forecasts are provided in terms of sales volume (W Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Ocular Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Ocular Drug Segment by Company

OCULAR THERAPEUTIX, INC
Alimera Sciences
Allergan, Plc
Clearside Biomedical
Envisia Therapeutics
EyeGate Pharma
Graybug Vision Inc
Taiwan Liposome Company
Valeant Pharmaceuticals International, Inc
Santen Pharmaceutical
Ocular Drug Segment by Type

In Situ Gel & Punctal Plugs
Ocular Insert
Intraocular Implants
Iontophoresis
Others
Ocular Drug Segment by Application

Homecare Settings
Ambulatory Surgical Centers
Ophthalmic Clinics
Hospitals
Ocular Drug Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Colombia
Middle East Middle East & Africa
Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ocular Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Ocular Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ocular Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Ocular Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Ocular Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Ocular Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

126 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Ocular Drug Market Size (2020-2031)
2.2.2 Global Ocular Drug Sales (2020-2031)
2.2.3 Global Ocular Drug Market Average Price (2020-2031)
2.3 Ocular Drug by Type
2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
2.3.2 In Situ Gel & Punctal Plugs
2.3.3 Ocular Insert
2.3.4 Intraocular Implants
2.3.5 Iontophoresis
2.3.6 Others
2.4 Ocular Drug by Application
2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.4.2 Homecare Settings
2.4.3 Ambulatory Surgical Centers
2.4.4 Ophthalmic Clinics
2.4.5 Hospitals
3 Market Competitive Landscape by Manufacturers
3.1 Global Ocular Drug Market Competitive Situation by Manufacturers (2020 Versus 2024)
3.2 Global Ocular Drug Sales (W Units) of Manufacturers (2020-2025)
3.3 Global Ocular Drug Revenue of Manufacturers (2020-2025)
3.4 Global Ocular Drug Average Price by Manufacturers (2020-2025)
3.5 Global Ocular Drug Industry Ranking, 2023 VS 2024 VS 2025
3.6 Global Manufacturers of Ocular Drug, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Ocular Drug, Product Type & Application
3.8 Global Manufacturers of Ocular Drug, Established Date
3.9 Global Ocular Drug Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 OCULAR THERAPEUTIX, INC
4.1.1 OCULAR THERAPEUTIX, INC Company Information
4.1.2 OCULAR THERAPEUTIX, INC Business Overview
4.1.3 OCULAR THERAPEUTIX, INC Ocular Drug Sales, Revenue and Gross Margin (2020-2025)
4.1.4 OCULAR THERAPEUTIX, INC Ocular Drug Product Portfolio
4.1.5 OCULAR THERAPEUTIX, INC Recent Developments
4.2 Alimera Sciences
4.2.1 Alimera Sciences Company Information
4.2.2 Alimera Sciences Business Overview
4.2.3 Alimera Sciences Ocular Drug Sales, Revenue and Gross Margin (2020-2025)
4.2.4 Alimera Sciences Ocular Drug Product Portfolio
4.2.5 Alimera Sciences Recent Developments
4.3 Allergan, Plc
4.3.1 Allergan, Plc Company Information
4.3.2 Allergan, Plc Business Overview
4.3.3 Allergan, Plc Ocular Drug Sales, Revenue and Gross Margin (2020-2025)
4.3.4 Allergan, Plc Ocular Drug Product Portfolio
4.3.5 Allergan, Plc Recent Developments
4.4 Clearside Biomedical
4.4.1 Clearside Biomedical Company Information
4.4.2 Clearside Biomedical Business Overview
4.4.3 Clearside Biomedical Ocular Drug Sales, Revenue and Gross Margin (2020-2025)
4.4.4 Clearside Biomedical Ocular Drug Product Portfolio
4.4.5 Clearside Biomedical Recent Developments
4.5 Envisia Therapeutics
4.5.1 Envisia Therapeutics Company Information
4.5.2 Envisia Therapeutics Business Overview
4.5.3 Envisia Therapeutics Ocular Drug Sales, Revenue and Gross Margin (2020-2025)
4.5.4 Envisia Therapeutics Ocular Drug Product Portfolio
4.5.5 Envisia Therapeutics Recent Developments
4.6 EyeGate Pharma
4.6.1 EyeGate Pharma Company Information
4.6.2 EyeGate Pharma Business Overview
4.6.3 EyeGate Pharma Ocular Drug Sales, Revenue and Gross Margin (2020-2025)
4.6.4 EyeGate Pharma Ocular Drug Product Portfolio
4.6.5 EyeGate Pharma Recent Developments
4.7 Graybug Vision Inc
4.7.1 Graybug Vision Inc Company Information
4.7.2 Graybug Vision Inc Business Overview
4.7.3 Graybug Vision Inc Ocular Drug Sales, Revenue and Gross Margin (2020-2025)
4.7.4 Graybug Vision Inc Ocular Drug Product Portfolio
4.7.5 Graybug Vision Inc Recent Developments
4.8 Taiwan Liposome Company
4.8.1 Taiwan Liposome Company Company Information
4.8.2 Taiwan Liposome Company Business Overview
4.8.3 Taiwan Liposome Company Ocular Drug Sales, Revenue and Gross Margin (2020-2025)
4.8.4 Taiwan Liposome Company Ocular Drug Product Portfolio
4.8.5 Taiwan Liposome Company Recent Developments
4.9 Valeant Pharmaceuticals International, Inc
4.9.1 Valeant Pharmaceuticals International, Inc Company Information
4.9.2 Valeant Pharmaceuticals International, Inc Business Overview
4.9.3 Valeant Pharmaceuticals International, Inc Ocular Drug Sales, Revenue and Gross Margin (2020-2025)
4.9.4 Valeant Pharmaceuticals International, Inc Ocular Drug Product Portfolio
4.9.5 Valeant Pharmaceuticals International, Inc Recent Developments
4.10 Santen Pharmaceutical
4.10.1 Santen Pharmaceutical Company Information
4.10.2 Santen Pharmaceutical Business Overview
4.10.3 Santen Pharmaceutical Ocular Drug Sales, Revenue and Gross Margin (2020-2025)
4.10.4 Santen Pharmaceutical Ocular Drug Product Portfolio
4.10.5 Santen Pharmaceutical Recent Developments
5 Global Ocular Drug Market Scenario by Region
5.1 Global Ocular Drug Market Size by Region: 2020 VS 2024 VS 2031
5.2 Global Ocular Drug Sales by Region: 2020-2031
5.2.1 Global Ocular Drug Sales by Region: 2020-2025
5.2.2 Global Ocular Drug Sales by Region: 2026-2031
5.3 Global Ocular Drug Revenue by Region: 2020-2031
5.3.1 Global Ocular Drug Revenue by Region: 2020-2025
5.3.2 Global Ocular Drug Revenue by Region: 2026-2031
5.4 North America Ocular Drug Market Facts & Figures by Country
5.4.1 North America Ocular Drug Market Size by Country: 2020 VS 2024 VS 2031
5.4.2 North America Ocular Drug Sales by Country (2020-2031)
5.4.3 North America Ocular Drug Revenue by Country (2020-2031)
5.4.4 United States
5.4.5 Canada
5.4.6 Mexico
5.5 Europe Ocular Drug Market Facts & Figures by Country
5.5.1 Europe Ocular Drug Market Size by Country: 2020 VS 2024 VS 2031
5.5.2 Europe Ocular Drug Sales by Country (2020-2031)
5.5.3 Europe Ocular Drug Revenue by Country (2020-2031)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Russia
5.5.9 Spain
5.5.10 Netherlands
5.5.11 Switzerland
5.5.12 Sweden
5.5.13 Poland
5.6 Asia Pacific Ocular Drug Market Facts & Figures by Country
5.6.1 Asia Pacific Ocular Drug Market Size by Country: 2020 VS 2024 VS 2031
5.6.2 Asia Pacific Ocular Drug Sales by Country (2020-2031)
5.6.3 Asia Pacific Ocular Drug Revenue by Country (2020-2031)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 Taiwan
5.6.10 Southeast Asia
5.7 South America Ocular Drug Market Facts & Figures by Country
5.7.1 South America Ocular Drug Market Size by Country: 2020 VS 2024 VS 2031
5.7.2 South America Ocular Drug Sales by Country (2020-2031)
5.7.3 South America Ocular Drug Revenue by Country (2020-2031)
5.7.4 Brazil
5.7.5 Argentina
5.7.6 Chile
5.7.7 Colombia
5.8 Middle East and Africa Ocular Drug Market Facts & Figures by Country
5.8.1 Middle East and Africa Ocular Drug Market Size by Country: 2020 VS 2024 VS 2031
5.8.2 Middle East and Africa Ocular Drug Sales by Country (2020-2031)
5.8.3 Middle East and Africa Ocular Drug Revenue by Country (2020-2031)
5.8.4 Egypt
5.8.5 South Africa
5.8.6 Israel
5.8.7 Türkiye
5.8.8 GCC Countries
6 Segment by Type
6.1 Global Ocular Drug Sales by Type (2020-2031)
6.1.1 Global Ocular Drug Sales by Type (2020-2031) & (W Units)
6.1.2 Global Ocular Drug Sales Market Share by Type (2020-2031)
6.2 Global Ocular Drug Revenue by Type (2020-2031)
6.2.1 Global Ocular Drug Sales by Type (2020-2031) & (US$ Million)
6.2.2 Global Ocular Drug Revenue Market Share by Type (2020-2031)
6.3 Global Ocular Drug Price by Type (2020-2031)
7 Segment by Application
7.1 Global Ocular Drug Sales by Application (2020-2031)
7.1.1 Global Ocular Drug Sales by Application (2020-2031) & (W Units)
7.1.2 Global Ocular Drug Sales Market Share by Application (2020-2031)
7.2 Global Ocular Drug Revenue by Application (2020-2031)
7.2.1 Global Ocular Drug Sales by Application (2020-2031) & (US$ Million)
7.2.2 Global Ocular Drug Revenue Market Share by Application (2020-2031)
7.3 Global Ocular Drug Price by Application (2020-2031)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Ocular Drug Value Chain Analysis
8.1.1 Ocular Drug Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Ocular Drug Production Mode & Process
8.2 Ocular Drug Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Ocular Drug Distributors
8.2.3 Ocular Drug Customers
9 Global Ocular Drug Analyzing Market Dynamics
9.1 Ocular Drug Industry Trends
9.2 Ocular Drug Industry Drivers
9.3 Ocular Drug Industry Opportunities and Challenges
9.4 Ocular Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.